Hoplite Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Hoplite Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-961,531	Closed	-$121M	–	33
2015 Q4	$121M	Sell	961,531 -70,317	-7%	-$8.49M	5.25%	7
2015 Q3	$107M	Buy	1,031,848 +68,529	+7%	+$8.8M	4.06%	11
2015 Q2	$119M	Buy	963,319 +328,114	+52%	+$41.3M	3.18%	16
2015 Q1	$74.9M	Buy	635,205 +28,650	+5%	+$3.43M	2.31%	22
2014 Q4	$72.1M	Buy	+606,555	New	+$68.3M	2%	23

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Hoplite Capital Management's VRTX Position: Q1 2016 in Review

Hoplite Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2016, closing a stake of 961,531 shares — an estimated $121M sold.

Hoplite Capital Management first reported a position in VRTX in Q4 2014 and held it in 5 quarters. The position peaked at $121M in Q4 2015. 502 funds tracked by Wall St. Rank hold VRTX as of Q1 2016.

Hoplite Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Hoplite Capital Management sold 961,531 Vertex Pharmaceuticals shares in Q1 2016, an estimated $121M.
Hoplite Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Hoplite Capital Management's Vertex Pharmaceuticals position peaked at $121M in Q4 2015.
502 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2016.

Based on Hoplite Capital Management's 13F filing for Q1 2016, filed 16 May 2016.